Standard BioTools Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Standard BioTools kazanç ve gelirinin sırasıyla yıllık 8.1% ve 16.4% oranında artması tahmin edilirken, EPS'nin yıllık 4.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

8.1%

Kazanç büyüme oranı

4.8%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.4%
Gelir büyüme oranı	16.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	04 Jan 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:76X0 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	140	-69	N/A	-81	2
12/31/2025	118	-84	N/A	-87	2
12/31/2024	99	-100	N/A	-91	4
12/31/2023	84	-111	N/A	-113	4
9/30/2023	82	-130	-122	-117	N/A
6/30/2023	101	-141	-139	-134	N/A
3/31/2023	95	-139	-144	-138	N/A
12/31/2022	98	-109	-106	-101	N/A
9/30/2022	102	-83	-96	-92	N/A
6/30/2022	80	-92	-75	-70	N/A
3/31/2022	86	-82	-46	-42	N/A
12/31/2021	82	-88	-44	-40	N/A
9/30/2021	87	-73	-27	-23	N/A
6/30/2021	81	-39	-13	-11	N/A
3/31/2021	68	-45	-22	-21	N/A
12/31/2020	56	-53	-29	-28	N/A
12/31/2019	32	-57	-51	-51	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 76X0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 76X0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 76X0 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 76X0 şirketinin gelirinin (yıllık 16.4% ) German pazarından (yıllık 5.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 76X0 şirketinin gelirinin (yıllık 16.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 76X0 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Standard BioTools Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 3Q 2022)

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.022 loss in 1Q 2022)

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

Less than half of directors are independent

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.64 loss in FY 2021)

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.30 loss in 3Q 2021)

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

SomaLogic Provides Revenue Guidance for the Full Year 2022

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.13 loss in 1Q 2021)

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings released: US$0.64 loss per share (vs US$0.81 loss in FY 2020)

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

Now 23% undervalued after recent price drop

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.55 loss per share

Director recently bought €136k worth of stock

No independent directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin